XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.3
REVENUE
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The Company’s revenue is primarily generated by its laboratory testing services utilizing its Cologuard and Oncotype® tests. The services are considered completed upon release of a patient’s test result to the ordering healthcare provider.
The following table presents the Company’s revenues disaggregated by revenue source:
Three Months Ended September 30,Nine Months Ended September 30,
(In thousands)2024202320242023
Screening
Medicare Parts B & C$201,423 $173,624 $570,550 $521,370 
Commercial289,637 253,401 827,509 732,182 
Other53,841 44,988 153,246 124,443 
Total Screening544,901 472,013 1,551,305 1,377,995 
Precision Oncology
Medicare Parts B & C$47,080 $46,383 $142,597 $141,352 
Commercial47,685 44,430 143,572 135,574 
International49,433 38,599 140,688 111,453 
Other19,556 26,913 67,281 80,552 
Total Precision Oncology163,754 156,325 494,138 468,931 
COVID-19 Testing$— $— $— $5,955 
Total$708,655 $628,338 $2,045,443 $1,852,881 
Screening revenue primarily includes laboratory service revenue from Cologuard and Prevention Genetics, LLC (“PreventionGenetics”) tests while Precision Oncology revenue primarily includes laboratory service revenue from global Oncotype DX and therapy selection tests.
At each reporting period end, the Company conducts an analysis of the estimates used to calculate the transaction price to determine whether any new information available impacts those estimates made in prior reporting periods. Adjustments to revenue recognized during the period relating to prior period estimates were less than 1% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2024. Adjustments to revenue recognized during the period relating to prior period estimates were less than 2% of revenue recorded in the Company’s condensed consolidated statement of operations for the three and nine months ended September 30, 2023.
The Company’s deferred revenue, which is reported in other current liabilities in the Company’s condensed consolidated balance sheets, was not significant as of September 30, 2024 and December 31, 2023.
Revenue recognized for the three and nine months ended September 30, 2024 and 2023 that was included in the deferred revenue balance at the beginning of the period was not significant.